Đánh giá kết quả sống thêm 10 năm hoá - xạ trị đồng thời sau phẫu thuật ung thư trực tràng giai đoạn II-III tại Bệnh viện K

The aims was to evaluate the effectiveness of survival in patients with stage II-III rectal cancer adjuvant given in chemoradiotherapy. Material/methods: From 2012 to 2017, a total of 75 patients with stage II-III rectal cancer at K hospital were evaluated retrospectively for the efficacy of postoperative chemoradiation. Survival data and factors affecting survival were analyzed. Results: Seventy-five patients received postoperative chemoradiotherapy, OS at 10 years was 52.0%. There was a statistically significant difference in overall survival (OS) according to preoperative CEA concentration ≤5 ng/ml was 96,2±6,2 months higher than the group with CEA > 5ng/ml was 54,6±5,8 months, with p=0.01% and median OS after surgery with CEA ≤5 ng/ml after surgery was 85,4±5,6 month higher than the group with CEA > 5ng/ml was 59,1±10,9 months with p =0.2%. OS for stages II and III was 96±6,3 months vs. 59,2±6,0 months. The median OS based on the location of rectal cancer was 86.2±15,5 months, 66.3±5.2 months, and 75.2±5.9 months, respectively (p=0.820). According to the LAR, Miles, and Hartmann procedures, the median OS was 87.4±6.8 months, 74.9±26.9 months, and 41.9±8.1 months, respectively (p=0.035). The median OS for well differentiated (low grade), moderately differentiated (intermediate grade), and poorly differentiated (high grade) cancers was 67.8±10.6 months, 83.76.3 months, and 67.7±9.0 months, respectively (p=0.98). Men had a median OS mean number of 89.0±6.7 months and women had a median OS mean number of 63±6.6 months (p=0.118). Conclusion: Postoperative chemoradiotherapy prolongs survival for patients with stage II-III rectal, there were significant differences in overall survival at 10 years according to CEA concentration before and after surgery, by stage.